GlobeNewsWire
11 Jun 2026, 12:45 UTC · 14w ago
Verdict
Headline takes no side. We score PALI +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Palisade Bio is advancing its lead candidate, PALI-2108, toward Phase 2 clinical development.
More positive than 77% of claims this week
Palisade Bio appointed Robert Baltera and Jordan Zwick, both with extensive experience in M&A and strategic transactions, to its Board of Directors.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 50% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company is strengthening its board with experienced industry veterans to support its clinical development and growth strategy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−3.8%
Price is moving against the score
$1.62 vs $1.68 close before publication (Jun 10) · not market-adjusted
PALI chart →